scholarly article | Q13442814 |
P50 | author | Richard D Wainford | Q56911165 |
Patrice Delafontaine | Q37387470 | ||
Tadashi Yoshida | Q39992835 | ||
Sergiy Sukhanov | Q41174548 | ||
P2093 | author name string | Daniel R Kapusta | |
Laura Semprun-Prieto | |||
P2860 | cites work | AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus | Q28254114 |
Central nervous system control of food intake | Q29547439 | ||
Role of neuropeptides in appetite regulation and obesity--a review. | Q30356494 | ||
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons | Q30479831 | ||
IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression | Q33840703 | ||
Candesartan cilexetil: an angiotensin II-receptor blocker | Q33901315 | ||
Mechanisms of cancer cachexia | Q34016887 | ||
Biology of cachexia | Q34065627 | ||
The syndrome of cardiac cachexia | Q34774425 | ||
Angiotensin II induced catabolic effect and muscle atrophy are redox dependent | Q35028013 | ||
Neuropeptides, food intake and body weight regulation: a hypothalamic focus | Q35048780 | ||
Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting | Q35240148 | ||
Hypothalamic control of energy balance: different peptides, different functions | Q35769125 | ||
Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome | Q35886214 | ||
Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? | Q36223165 | ||
Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. | Q36248631 | ||
WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILURE | Q57628891 | ||
Activation/deactivation of renal Na+,K(+)-ATPase: a final common pathway for regulation of natriuresis | Q72387481 | ||
Characterisation of 5'-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5'-AMP analogues on enzyme activity | Q72425499 | ||
Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment | Q72889565 | ||
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure | Q73301653 | ||
Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I | Q73620065 | ||
Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases | Q78036425 | ||
Neuroendocrine control of food intake | Q80151225 | ||
From genetics to mechanism of disease liability | Q80930874 | ||
Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma | Q36403518 | ||
Angiotensin II as candidate of cardiac cachexia | Q36445136 | ||
Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice | Q36877911 | ||
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting | Q37123224 | ||
Immunoregulators in the nervous system | Q37181575 | ||
The value of current interventions for obesity | Q37200553 | ||
Neural networks of several novel neuropeptides involved in feeding regulation | Q37251388 | ||
AMPK: a metabolic gauge regulating whole-body energy homeostasis | Q37314854 | ||
The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis | Q37328877 | ||
Cardiac cachexia: a systematic overview | Q37343128 | ||
Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism | Q37355630 | ||
Candesartan cilexetil in the treatment of chronic heart failure | Q37479043 | ||
ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial | Q37563491 | ||
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? | Q37629411 | ||
Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention | Q37831670 | ||
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice | Q39798655 | ||
Role of neuronal energy status in the regulation of adenosine 5'-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior | Q40514639 | ||
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting | Q40891663 | ||
Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options | Q40896872 | ||
Anorexia during acute and chronic disease | Q41047136 | ||
Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. | Q41621710 | ||
Angiotensin II type 1 receptor signaling regulates feeding behavior through anorexigenic corticotropin-releasing hormone in hypothalamus | Q42001876 | ||
Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase | Q42491855 | ||
Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter | Q43709987 | ||
Role of AT2 receptor in the brain in regulation of blood pressure and water intake | Q44185525 | ||
Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling | Q46291378 | ||
Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase | Q46368505 | ||
Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor | Q46477287 | ||
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. | Q46493539 | ||
Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons | Q46858899 | ||
Anticytokine approaches to the treatment of anorexia and cachexia. | Q47979150 | ||
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate | Q47979162 | ||
Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity | Q48375233 | ||
AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats. | Q51372264 | ||
Circulating Renin Angiotensin System in Childhood Chronic Renal Failure: Marked Increase of Angiotensin-(1–7) in End-Stage Renal Disease | Q56775014 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1411-1420 | |
P577 | publication date | 2012-01-10 | |
P1433 | published in | Endocrinology | Q3054009 |
P1476 | title | Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus | |
P478 | volume | 153 |